AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET
01 Marzo 2024 - 6:07PM
UK Regulatory
AB Science will host a live webcast on Monday March 4, 2024, from
6.30pm to 7.30pm CET
PRESS RELEASE
AB SCIENCE WILL HOST A LIVE WEBCAST ON
MONDAY MARCH 4, 2024 FROM 6.30PM TO 7.30PM CET
Paris, 1 March, 2024, 6pm CET
AB Science SA (Euronext –
FR0010557264 – AB) will host a live webcast on Monday March 4,
2024, from 6.30pm to 7.30pm CET.
The agenda of this live webcast will be to provide status and
perspective on the following topics:
- Conditional approval of masitinib
in ALS with EMA and Health Canada
- Partnership strategy
- Masitinib platform clinical
development program
- Microtubulin platform development
program
- Intellectual property
The presentation will be followed by a Q&A
session.
Webcast Information
- Webcast date: Monday, March 4,
2024. US: 12.30pm-1.30pm ET; Europe: 6.30pm-7.30pm CET
- Access to the webcast (audio +
presentation) : Access to the webcast
About AB Science
Founded in 2001, AB Science is a pharmaceutical company
specializing in the research, development and commercialization of
protein kinase inhibitors (PKIs), a class of targeted proteins
whose action are key in signaling pathways within cells. Our
programs target only diseases with high unmet medical needs, often
lethal with short term survival or rare or refractory to previous
line of treatment.
AB Science has developed a proprietary portfolio of molecules and
the Company’s lead compound, masitinib, has already been registered
for veterinary medicine and is developed in human medicine in
oncology, neurological diseases, inflammatory diseases and viral
diseases. The company is headquartered in Paris, France, and listed
on Euronext Paris (ticker: AB).
Further information is available on AB Science’s website:
www.ab-science.com.
Forward-looking Statements - AB
Science
This press release contains forward-looking statements. These
statements are not historical facts. These statements include
projections and estimates as well as the assumptions on which they
are based, statements based on projects, objectives, intentions and
expectations regarding financial results, events, operations,
future services, product development and their potential or future
performance.
These forward-looking statements can often be
identified by the words "expect", "anticipate", "believe",
"intend", "estimate" or "plan" as well as other similar terms.
While AB Science believes these forward-looking statements are
reasonable, investors are cautioned that these forward-looking
statements are subject to numerous risks and uncertainties that are
difficult to predict and generally beyond the control of AB Science
and which may imply that results and actual events significantly
differ from those expressed, induced or anticipated in the
forward-looking information and statements. These risks and
uncertainties include the uncertainties related to product
development of the Company which may not be successful or to the
marketing authorizations granted by competent authorities or, more
generally, any factors that may affect marketing capacity of the
products developed by AB Science, as well as those developed or
identified in the public documents published by AB Science. AB
Science disclaims any obligation or undertaking to update the
forward-looking information and statements, subject to the
applicable regulations, in particular articles 223-1 et seq. of the
AMF General Regulations.
For additional information, please contact:
AB Science
Financial Communication & Media Relations
investors@ab-science.com
- Webcast AB Science VEng VF
Grafico Azioni Ab Science (LSE:0Q77)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Ab Science (LSE:0Q77)
Storico
Da Dic 2023 a Dic 2024